Nomura Maintains Buy on Biogen, Raises Price Target to $392

Nomura analyst Christopher Marai maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $320 to $392.

Benzinga · 02/07/2020 12:44

Nomura analyst Christopher Marai maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $320 to $392.